Innate Pharma S.A.

OTCPK:IPHY.F Stock Report

Market Cap: US$162.9m

Innate Pharma Valuation

Is IPHY.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of IPHY.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: IPHY.F ($2.16) is trading below our estimate of fair value ($7.76)

Significantly Below Fair Value: IPHY.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPHY.F?

Key metric: As IPHY.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IPHY.F. This is calculated by dividing IPHY.F's market cap by their current revenue.
What is IPHY.F's PS Ratio?
PS Ratio11.1x
Sales€12.64m
Market Cap€139.93m

Price to Sales Ratio vs Peers

How does IPHY.F's PS Ratio compare to its peers?

The above table shows the PS ratio for IPHY.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.4x
SGMO Sangamo Therapeutics
4.6x42.73%US$151.1m
IRD Opus Genetics
10.1x40.73%US$141.4m
ALEC Alector
3x-10.33%US$200.8m
CRBU Caribou Biosciences
16x50.78%US$147.7m
IPHY.F Innate Pharma
11.1x38.08%US$139.9m

Price-To-Sales vs Peers: IPHY.F is expensive based on its Price-To-Sales Ratio (11.1x) compared to the peer average (8.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does IPHY.F's PS Ratio compare vs other companies in the US Biotechs Industry?

121 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.6x-1.24%US$27.23b
BMRN BioMarin Pharmaceutical
3.4x5.45%US$11.09b
PTCT PTC Therapeutics
3.4x1.51%US$6.23b
ALKS Alkermes
3.2x8.81%US$4.89b
IPHY.F 11.1xIndustry Avg. 12.5xNo. of Companies121PS01632486480+
121 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IPHY.F is good value based on its Price-To-Sales Ratio (11.1x) compared to the US Biotechs industry average (12.5x).

Price to Sales Ratio vs Fair Ratio

What is IPHY.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPHY.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IPHY.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPHY.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$7.17
0%
0.81%US$7.23US$7.12n/a2
Jan ’27n/a
US$5.64
0%
36.21%US$7.15US$2.75n/a3
Dec ’26US$1.99
US$5.64
+183.58%
36.21%US$7.15US$2.75n/a3
Nov ’26n/a
US$5.64
0%
38.16%US$7.22US$2.60n/a3
Oct ’26n/a
US$5.81
0%
35.01%US$7.31US$2.93n/a3
Sep ’26n/a
US$5.04
0%
42.69%US$7.19US$2.89n/a2
Aug ’26n/a
US$5.04
0%
42.69%US$7.19US$2.89n/a2
Jul ’26US$1.95
US$5.45
+179.69%
34.27%US$7.05US$2.83n/a3
Jun ’26n/a
US$6.47
0%
37.07%US$9.54US$2.83n/a4
May ’26n/a
US$7.02
0%
34.54%US$9.60US$2.78n/a5
Apr ’26n/a
US$6.65
0%
34.67%US$9.09US$2.61n/a5
Mar ’26n/a
US$6.44
0%
34.67%US$8.81US$2.53n/a5
Feb ’26n/a
US$6.40
0%
34.67%US$8.75US$2.51n/a5
Jan ’26n/a
US$6.40
0%
34.67%US$8.75US$2.51n/a5
Dec ’25n/a
US$6.40
0%
34.67%US$8.75US$2.51US$1.995
Nov ’25n/a
US$6.71
0%
35.78%US$9.22US$2.47n/a5
Oct ’25US$2.25
US$6.88
+206.28%
39.17%US$9.30US$2.49n/a4
Sep ’25n/a
US$6.74
0%
37.16%US$9.03US$2.69n/a4
Aug ’25n/a
US$6.74
0%
37.16%US$9.03US$2.69n/a4
Jul ’25n/a
US$7.05
0%
36.31%US$9.15US$2.72US$1.954
Jun ’25n/a
US$6.83
0%
33.63%US$9.08US$2.70n/a5
May ’25n/a
US$6.79
0%
35.34%US$9.10US$2.44n/a5
Apr ’25US$2.58
US$6.79
+163.21%
35.34%US$9.10US$2.44n/a5
Mar ’25n/a
US$6.79
0%
33.63%US$9.02US$2.69n/a5
Feb ’25n/a
US$6.87
0%
33.63%US$9.14US$2.72n/a5
Jan ’25US$2.84
US$6.87
+142.07%
33.63%US$9.14US$2.72n/a5
US$8.73
Fair Value
75.3% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/14 19:54
End of Day Share Price 2025/12/16 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Innate Pharma S.A. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research